Jacobs & Co. CA grew its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 9.9% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 113,257 shares of the company’s stock after purchasing an additional 10,204 shares during the period. Jacobs & Co. CA’s holdings in Merck & Co., Inc. were worth $8,731,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently modified their holdings of MRK. Wealth Alliance boosted its position in shares of Merck & Co., Inc. by 9.6% during the 3rd quarter. Wealth Alliance now owns 21,155 shares of the company’s stock worth $1,755,000 after purchasing an additional 1,845 shares in the last quarter. ExodusPoint Capital Management LP purchased a new stake in shares of Merck & Co., Inc. in the 3rd quarter worth about $1,310,000. OLD Mission Capital LLC purchased a new stake in shares of Merck & Co., Inc. in the 3rd quarter worth about $247,000. First Commonwealth Financial Corp PA boosted its position in shares of Merck & Co., Inc. by 5.5% in the 3rd quarter. First Commonwealth Financial Corp PA now owns 4,154 shares of the company’s stock worth $344,000 after buying an additional 217 shares in the last quarter. Finally, Advisory Alpha LLC purchased a new stake in shares of Merck & Co., Inc. in the 3rd quarter worth about $130,000. Institutional investors own 72.86% of the company’s stock.
Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Merck & Co., Inc. in a research report on Friday, February 5th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $95.92.
Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Wednesday, February 3rd. The company reported $1.32 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.06). Merck & Co., Inc. had a net margin of 24.33% and a return on equity of 53.83%. The firm had revenue of $12.51 billion during the quarter, compared to analyst estimates of $12.65 billion. During the same period in the previous year, the firm posted $1.16 EPS. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Merck & Co., Inc. will post 5.9 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Wednesday, April 7th. Investors of record on Monday, March 15th were paid a $0.65 dividend. This represents a $2.60 annualized dividend and a yield of 3.42%. The ex-dividend date of this dividend was Friday, March 12th. Merck & Co., Inc.’s payout ratio is 50.10%.
Merck & Co., Inc. Profile
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as and vaccine products.
Recommended Story: What are gap-down stocks?
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.